Insight

Mattia Rediti: Our work describing HER2-positive Breast Cancer heterogeneity is out

Mattia Rediti/LinkedIn

Dec 2, 2024, 08:12

Mattia Rediti: Our work describing HER2-positive Breast Cancer heterogeneity is out

Mattia Rediti, Medical Oncologist and Bioinformatician and AIRC Postdoctoral researcher at the Metabolic reprogramming in solid tumors Lab, IFOM, shared an article on LinkedIn:

“Our work describing HER2-positive breast cancer heterogeneity (from my PhD with Christos Sotiriou at Institut Jules Bordet) is out in Nature communications.

We identified 5 molecular subtypes in the ALTTO clinical trial (BIG against breast cancer) with external validations.
We captured both tumor-intrinsic and microenvironment features.
The subtypes showed prognostic value and, in neoadjuvant cohorts, differences in pCR rates.

Grateful to Christos Sotiriou for his guidance, the team at the BCTL, and all co-Authors.”

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

Authors: Mattia Rediti, et al.

Mattia Rediti: Our work describing HER2-positive Breast Cancer heterogeneity is out

AIRC Breast Cancer cancer Christos Sotiriou fight against cancer Global fight against cancer HER2 ifom Institut Jules Bordet Mattia Rediti MedOnc Nature Communications OncoDaily Oncology

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Special Coverage